Nurix’s Bexobrutideg Shows 22.1-Month PFS in Heavily Pretreated CLL
Nurix's bexobrutideg demonstrates 22.1-month median progression-free survival in heavily pretreated CLL patients, including those with BTK resistance mutations.
Spatial CRISPR Screening Just Made Your Preclinical Models Look Like Guesswork
Nature Biotechnology's Perturb-DBiT maps CRISPR perturbations in native tissue — and exposes why dissociated-cell screens keep producing trials that...
CytoDyn Starts Phase 2a Trial of Leronlimab in Early Alzheimer’s Disease
CytoDyn starts Phase 2a trial of leronlimab in early Alzheimer's disease, using PET imaging to measure microglial activation and...
Budoprutug Shows Response in Rituximab-Experienced ITP Patients
Budoprutug shows response in rituximab-experienced ITP patients in Phase 1b data, with three of four prior-treated patients achieving durable...
TransCon PTH Shows 82% Response Rate in 5-Year Hypoparathyroidism Trial
TransCon PTH achieved 82% response rate in a 5-year hypoparathyroidism trial, with 95% of patients completing the study and...
Cemsidomide Shows 53% Response Rate in Heavily Pretreated Myeloma
Cemsidomide shows 53% response rate in heavily pretreated myeloma patients, with responses deepening over time and manageable safety profile...
Ziftomenib Plus Chemotherapy Shows 94% Survival in NPM1-Mutant AML
Ziftomenib plus chemotherapy achieves 94% twelve-month survival in newly diagnosed NPM1-mutant AML patients in the KOMET-007 trial.
CNS Gene Therapy Trials Are About to Break Every Monitoring Assumption Your CRO Has
BBM-P002's multicenter Phase 1 Parkinson's data signals a wave of CNS gene therapy trials that will overwhelm standard eClinical...
The Single Phase 3 Default Is Already Changing How Sites Get Activated — Are You Ready?
FDA's February 2026 single-trial default standard is compressing enrollment timelines and reshaping site contracts. Here's what ops teams must...
Elixiron’s Enrupatinib Shows Neuroinflammation Reduction in Phase 2 Alzheimer’s Trial
Elixiron's enrupatinib reduced neuroinflammation signals by over 30% in biomarker-selected Alzheimer's patients within 28 days of dosing.